Digital Information Services
Membership | FAQ | About | Contact | Home 
Indonesia Companies Indonesia Contact Persons Indonesia Tariffs and Trade
Industry Market Research and Reports Global Industry Market Research Industry Market Research
Search databases

Dankos Farma, PT Live Support What's my password?

Company News
Kalbe, Dankos, and Enseval Merger Approved
Koran Tempo, page A20, 2005-11-30
Shareholders approve of the merger among PT Kalbe Farma Tbk, PT Dankos Laboratories Tbk, and PT Enseval. If all goes well, the merged company’s shares will be effective on January 2 2006 in the stock market. One Dankos note will be convered to 1.34 Kalbe notes. One Enseval note will be converted to 12,998.8 Kalbe notes. For the shareholders who do not approve of the merge, their shares will be accepted by the company, represented by PT Kresna Graha Sekurindo. Every Kalbe share will be worth Rp.850, Dankos Rp.1,140, and Enseval worth Rp.11 million per share. With this merge, Kalbe Farma will issue new 2 million new shares, from 8.12 billion to 10.16 billion shares. Kalbe Farma and Dankos shares owned by the public (less than 5 percent) decreased from 59.1 percent to 36.87 percent. The assets from the three companies before the merge will also drop from Rp.9.54 trillion to Rp.4.8trillion. Kalbe Farma predicts a growth increase of 15 percent. Sales and profit are hoped to increase 18 percent. The post-merger capitalization is hoped to exceed US$1 billion from its current position of US$700 million.
The Merger of 3 Pharmaceutical Companies
Kompas, page 19, 2005-11-19
Three pharmaceutical companies, PT Enseval, PT Kalbe Farma Tbk and PT Dankos Laboratories Tbk, all managed by the same business group, have decided to merge as Kalbe Farma. With the merger, Kalbe Farma targets to become the largest pharmaceutical company in Southeast Asia, especially for pharmaceutical products. The merged companies would have a capitalized market value of approximately US$ 1 billion.

Copyright & Disclaimer
PT. Dataindo Inti Swakarsa makes no representation to any other person with regard to the completeness or accuracy of the data or information contained herein, and it accepts no responsibility and disclaims all liability (save for liability which cannot be lawfully disclaimed) for loss or damage whatsoever suffered or incurred by any other person resulting from the use of, or reliance upon, the features, functions, tools, data or information contained herein.Information provided is not financial product advice. This report contains general information only. It is not intended as financial product advice and must not be relied upon as such. You should consider obtaining independent advice tailored to your specific circumstances before making any financial decisions. Copyright in this publication is owned by PT. Dataindo Inti Swakarsa. The publication is sold on the basis that the purchaser agrees not to copy the material contained within it for other than the purchasers own purposes. In the event that the purchaser uses or quotes from the material in this publication - in papers, reports, or opinions prepared for any other person - it is agreed that it will be sourced to: PT. Dataindo Inti Swakarsa

Dankos Farma, PT
Indonesia Company Report
Last Update 21-February-2013
Major Businessline : Pharmaceutical

PT. Dataindo Inti SwakarsaTelp : (62 - 21) 719 3832
3rd Floor, Gapura Raya BuildingTelp : (62 - 21) 719 3834
Jl. Bangka Raya No. 4, Pela Mampang Email :
Jakarta 12720, Indonesia
Selective Member’s Information US $ Select
Address 0.00
Telephone number(s) [1] 0.15
Facsimile number(s) [1] 0.30
Personnel (Director [1]) 0.35
Business Activity 0.30
Legality (Ownership Type) 0.25
Number of employees 0.55
Certification(s) [4] 0.50
Brands / Trade Mark 0.55
Additional Information 0.50
Dankos Projects Increase in Sales 0.20
PT Dankos Projects Sales to Increase by 30 Percent 0.20
Dankos Pays Obligation Debt 0.20
Dankos Develops Export Market 0.20
Dankos’ Performance for Semester I Improves 0.20
Selective Member`s Discount Price
To become a Selective Member